Marker Therapeutics
MRKR
29 hedge funds and large institutions have $5.78M invested in Marker Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
311% more capital invested
Capital invested by funds: $1.41M → $5.78M (+$4.38M)
1.3% less ownership
Funds ownership: 22.5% → 21.2% (-1.3%)
3% less funds holding
Funds holding: 30 → 29 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$53K |
| 2 |
VF
Virtu Financial
New York
|
+$35.6K |
| 3 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
+$26.1K |
| 4 |
Renaissance Technologies
New York
|
+$21.9K |
| 5 |
HF
HRT Financial
New York
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$104K |
| 2 |
Millennium Management
New York
|
-$22K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.13K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.25K |
MRKR Hedge Fund Activity: Q2 2023 in Review
29 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2023, worth a combined $5.78M — up 311% from $1.41M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MRKR and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Wedbush Securities, adding an estimated $53K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $104K sold.
- 29 institutional investors held Marker Therapeutics (MRKR) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $5.78M of Marker Therapeutics stock for Q2 2023, up 311% quarter-over-quarter.
- 4 funds opened new Marker Therapeutics positions in Q2 2023 and 5 closed out, a net change of -1 holder.
- The largest Marker Therapeutics buyer in Q2 2023 was Wedbush Securities, an estimated $53K added.
- The largest Marker Therapeutics seller in Q2 2023 was Long Focus Capital Management, an estimated $104K sold.
Based on aggregated 13F filings for Q2 2023.